{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '5.4.6.', 'Benefits of Trial Participation', 'Study subjects will receive regular medical care for the duration of the study. Subjects may', 'experience a reduction in the number of angioedema events if they are randomized to a', 'BCX7353 treatment. The development of BCX7353 is expected to be of benefit to the wider', 'community/patients with HAE.', '5.4.7.', 'Overall Benefit-Risk Assessment', 'The risks from daily oral administration of BCX7353 seen to date in both nonclinical and clinical', 'studies were primarily mild, monitorable, and reversible. Based on the utility of other kallikrein', 'inhibitors, such as C1-INH, the pharmacology of BCX7353, and Phase 3 data from', 'Study BCX7353-302, there is an expectation of benefit to the individual subject. The information', 'obtained from this study will support the development of BCX7353 for HAE, a serious,', 'debilitating, and potentially life-threatening disease. The overall benefit-risk balance is therefore', 'considered to be acceptable.', '6.', 'TRIAL OBJECTIVES', '6.1.', 'Objectives', '6.1.1.', 'Part 1 Primary Objective', 'To determine the efficacy of BCX7353 110 and 150 mg QD administered for', '24 weeks compared to placebo in the prevention of angioedema events in subjects', 'with HAE', '6.1.2.', 'Part 1 Secondary Objectives', 'To assess the safety and tolerability of BCX7353 110 and 150 mg QD administered', 'for 24 weeks', 'To assess the effects of BCX7353 on HAE disease activity and angioedema event', 'characteristics', 'To evaluate the effects of BCX7353 on QoL', 'To characterize the PD effects of BCX7353', '6.1.3.', 'Part 2 Primary Objective', 'To evaluate the long-term safety and tolerability of BCX7353 110 and 150 mg in', 'subjects with HAE', '6.1.4.', 'Part 2 Secondary Objectives', 'To assess the effectiveness (ie, angioedema event frequency over time) of BCX7353', 'over a 24- to 52-week administration period', 'To evaluate QoL and HAE disease activity of BCX7353 over a 24- to 52-week', 'administration period', '35']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'To evaluate subject satisfaction with BCX7353 over a 24- to 52-week administration', 'period', '6.1.5.', 'Part 3 Primary Objectives', 'To evaluate the long-term safety and tolerability of BCX7353 administered QD over', 'a 52- to up to 104-week administration period in subjects with HAE', '6.1.6.', 'Part 3 Secondary Objectives', 'To assess the effectiveness (ie, angioedema event frequency over time) of BCX7353', 'over a 52- to up to 104-week administration period', 'To evaluate QoL and HAE disease activity of BCX7353 over a 52- - to up to 104-week', 'administration period', 'To evaluate subject satisfaction with BCX7353 over a 52- to up to 104-week', 'administration period', '7.', 'OVERALL STUDY DESIGN AND PLAN', 'This is a randomized, placebo-controlled, double-blind, parallel-group, 3-part study. Part 1 is', 'designed to test the hypothesis that the angioedema event rate during 24 weeks of prophylactic', 'BCX7353 treatment at 2 dosage levels will be less than that observed during 24 weeks of', \"placebo. An angioedema event is defined as an attack, symptoms, or swelling due to a subject's\", 'underlying hereditary angioedema disease. The primary efficacy endpoint will be assessed after', 'the last subject completes Part 1 (through Week 24). Part 2 is designed to primarily evaluate the', 'long-term safety of BCX7353. Part 3 is open-label and designed to primarily evaluate the', 'long-term safety of BCX7353. Parts 1, 2, and 3 will be conducted in sequence. All subjects will', 'receive BCX7353 in Parts 2 and 3, including those randomized to receive placebo in Part 1.', 'In addition, efficacy data in Part 1, where appropriate, will be statistically analyzed by', 'combining data from this study with data from Study BCX7353-302 to ensure adequate', 'statistical power.', 'Part 1 (24-week evaluation of blinded efficacy and safety)', 'Subjects with HAE Type 1 or 2 will be eligible for the study following assessment of data', 'obtained from screening procedures, including demonstration of a minimum number of', 'qualifying angioedema events documented during a prospective run-in period of 8 weeks from', 'the date of the screening visit.', 'Approximately 24 treatment-eligible subjects > 12 years of age will receive study drug', '(BCX7353 or placebo) in Part 1 of the study based on randomization in a 1:1:1 ratio into one of', '3 treatment groups:', 'Group 1 (N=8): BCX7353 110 mg QD administered orally for 24 weeks', 'Group 2 (N=8): BCX7353 150 mg QD administered orally for 24 weeks', 'Group 3 (N=8): Placebo administered orally QD for 24 weeks', '36']\n\n###\n\n", "completion": "END"}